Statins and Vascular dementia: A review

Journal of Alzheimer's Disease

Volumn 42, Issue , 2014, Pages S315-S320

  Giannopoulos, Sotirios ^a   Katsanos, Aristeidis H ^a   Kosmidou, Maria ^a   Tsivgoulis, Georgios ^b,c  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

Author keywords

Cholesterol; HMG CoA inhibitors; lipid lowering agents; statins; vascular dementia

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT;

ARTERIAL WALL THICKNESS; BLOOD BRAIN BARRIER; BRAIN BLOOD FLOW; CHOLESTEROL BLOOD LEVEL; CONFERENCE PAPER; CROSS-SECTIONAL STUDY; DRUG EFFECT; HUMAN; HYPERLIPIDEMIA; INCIDENCE; MULTIINFARCT DEMENTIA; OBSERVATIONAL STUDY; TREATMENT DURATION; TREATMENT OUTCOME; BIBLIOGRAPHIC DATABASE; DEMENTIA, VASCULAR; STATISTICS AND NUMERICAL DATA;

ANTICHOLESTEREMIC AGENTS; DATABASES, BIBLIOGRAPHIC; DEMENTIA, VASCULAR; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS;

EID: 84920622055     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-132366     Document Type: Conference Paper

References (43)

1. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA (2000) Statins and the risk of dementia. Lancet 356, 1627-1631.
2. Wolozin B, Wang SW, Li NC, Lee A, Lee TA, Kazis LE (2007) Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease. BMC Med 5, 20.
3. Cramer C, Haan MN, Galea S, Langa KM, Kalbfleisch JD (2008) Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study. Neurology 71, 344-350.
4. Wong WB, Lin VW, Boudreau D, Devine EB (2013) Statins in the prevention of dementia and Alzheimer's disease: A meta-analysis of observational studies and an assessment of confounding. Pharmacoepidemiol Drug Saf 22, 345-358.
5. Carlsson CM, Nondahl DM, Klein BE, McBride PE, Sager MA, Schubert CR, Klein R, Cruickshanks KJ (2009) Increased atherogenic lipoproteins are associated with cognitive impairment: Effects of statins and subclinical atherosclerosis. Alzheimer Dis Assoc Disord 23, 11-17.
6. Benito-Leon J, Louis ED, Vega S, Bermejo-Pareja F (2010) Statins and cognitive functioning in the elderly:Apopulationbased study. J Alzheimers Dis 21, 95-102.
7. Ligthart SA, Moll van Charante EP, Van Gool WA, Richard E (2010) Treatment of cardiovascular risk factors to prevent cognitive decline and dementia: A systematic review. Vasc Health Risk Manag 6, 775-785.
8. Ancelin ML, Carriere I, Barberger-Gateau P, Auriacombe S, Rouaud O, Fourlanos S, Berr C, Dupuy AM, RitchieK(2012) Lipid lowering agents, cognitive decline, and dementia: The three-city study. J Alzheimers Dis 30, 629-637.
9. Wagstaff LR, Mitton MW, Arvik BM, Doraiswamy PM (2003) Statin-associated memory loss: Analysis of 60 case reports and review of the literature. Pharmacotherapy 23, 871-880.
10. Heart Protection Study Collaborative G (2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 360, 7-22.
11. Trompet S, van Vliet P, de Craen AJ, Jolles J, Buckley BM, Murphy MB, Ford I, Macfarlane PW, Sattar N, Packard CJ, Stott DJ, Shepherd J, Bollen EL, Blauw GJ, Jukema JW, Westendorp RG (2010) Pravastatin and cognitive function in the elderly. Results of the PROSPER study. J Neurol 257, 85-90.
12. Muangpaisan W, Brayne C, Alzheimer's Society Vascular Dementia Systematic Review G (2010) Systematic review of statins for the prevention of vascular dementia or dementia. Geriatr Gerontol Int 10, 199-208.
13. McGuinness B, O'Hare J, Craig D, Bullock R, Malouf R, Passmore P (2010) Statins for the treatment of dementia. Cochrane Database Syst Rev, Art No.: CD007514. DOI: 10.1002/14651858.CD007514
14. McGuinness B, O'Hare J, Craig D, Bullock R, Malouf R, Passmore P (2013) Cochrane review on 'Statins for the treatment of dementia'. Int J Geriatr Psychiatry 28, 119-126.
15. Fei M, Yan Ping Z, Ru Juan M, NingNing L, Lin G (2013) Risk factors for dementia with type 2 diabetes mellitus among elderly people in China. Age Ageing 42, 398-400.
16. Hajjar I, Schumpert J, Hirth V,Wieland D, Eleazer GP (2002) The impact of the use of statins on the prevalence of dementia and the progression of cognitive impairment. J Gerontol A Biol Sci Med Sci 57, M414-M418.
17. Rea TD, Breitner JC, Psaty BM, Fitzpatrick AL, Lopez OL, Newman AB, Hazzard WR, Zandi PP, Burke GL, Lyketsos CG, Bernick C, Kuller LH (2005) Statin use and the risk of incident dementia: The Cardiovascular Health Study. Arch Neurol 62, 1047-1051.
18. Reitz C, Tang MX, Luchsinger J, Mayeux R (2004) Relation of plasma lipids to Alzheimer disease and vascular dementia. Arch Neurol 61, 705-714.
19. Trkanjec Z, Bene R, Martinic-Popovic I, Jurasic JM, Lisak M, SericV, DemarinV(2009) Serum HDL,LDLand total cholesterol in patients with late-life onset of Alzheimer's disease versus vascular dementia. Acta Clin Croat 48, 259-263.
20. Solomon A, Kivipelto M, Wolozin B, Zhou J, Whitmer RA (2009) Midlife serum cholesterol and increased risk of Alzheimer's and vascular dementia three decades later. Dement Geriatr Cogn Disord 28, 75-80.
21. Anstey KJ, Lipnicki DM, Low LF (2008) Cholesterol as a risk factor for dementia and cognitive decline: A systematic review of prospective studies with meta-analysis. Am J Geriatr Psychiatry 16, 343-354.
22. Dantoine TF, Debord J, Merle L, Lacroix-Ramiandrisoa H, Bourzeix L, Charmes JP (2002) Paraoxonase 1 activity: A new vascular marker of dementia? Ann N Y Acad Sci 977, 96-101.
23. Paragh G, Balla P, Katona E, Seres I, Egerhazi A, Degrell I (2002) Serum paraoxonase activity changes in patients with Alzheimer's disease and vascular dementia. Eur Arch Psychiatry Clin Neurosci 252, 63-67.
24. Li L, Willets RS, Polidori MC, Stahl W, Nelles G, Sies H, Griffiths HR (2010) Oxidative LDL modification is increased in vascular dementia and is inversely associated with cognitive performance. Free Radic Res 44, 241-248.
25. Fiolaki A, Tsamis KI, Milionis HJ, Kyritsis AP, Kosmidou M, Giannopoulos S (2014) Atherosclerosis, biomarkers of atherosclerosis and Alzheimer's disease. Int J Neurosci 124, 1-11.
26. Ban Y, Watanabe T, Miyazaki A, Nakano Y, Tobe T, Idei T, Iguchi T, Ban Y, Katagiri T (2007) Impact of increased plasma serotonin levels and carotid atherosclerosis on vascular dementia. Atherosclerosis 195, 153-159.
27. Ban Y,Watanabe T, Suguro T, Matsuyama TA, Iso Y, Sakai T, Sato R, Idei T, Nakano Y, Ota H, Miyazaki A, Kato N, Hirano T, Ban Y, Kobayashi Y (2009) Increased plasma urotensin-II and carotid atherosclerosis are associated with vascular dementia. J Atheroscler Thromb 16, 179-187.
28. Breteler MM, Claus JJ, Grobbee DE, Hofman A (1994) Cardiovascular disease and distribution of cognitive function in elderly people: The Rotterdam Study. BMJ 308, 1604-1608.
29. Antonopoulos AS, Margaritis M, Lee R, Channon K, Antoniades C (2012) Statins as anti-inflammatory agents in atherogenesis: Molecular mechanisms and lessons from the recent clinical trials. Curr Pharm Des 18, 1519-1530.
30. Giannopoulos S, Katsanos AH, Tsivgoulis G, Marshall RS (2012) Statins and cerebral hemodynamics. J Cereb Blood Flow Metab 32, 1973-1976.
31. Kast RE (2001) Dementia and statins. Lancet 357, 881.
32. Vaughan CJ (2003) Prevention of stroke and dementia with statins: Effects beyond lipid lowering. Am J Cardiol 91, 23B-29B.
33. Gorelick PB, Scuteri A, Black SE, Decarli C, Greenberg SM, Iadecola C, Launer LJ, Laurent S, Lopez OL, Nyenhuis D, Petersen RC, Schneider JA, Tzourio C, Arnett DK, Bennett DA, Chui HC, Higashida RT, Lindquist R, Nilsson PM, Roman GC, Sellke FW, Seshadri S, American Heart Association Stroke Council CoE, Prevention CoCNCoCR, Intervention, Council on Cardiovascular S, Anesthesia (2011) Vascular contributions to cognitive impairment and dementia: A statement for healthcare professionals from the American heart association/American stroke association. Stroke 42, 2672-2713.
34. O'Brien JT, Burns A, Group BAPDC (2011) Clinical practice with anti-dementia drugs:Arevised (second) consensus statement from the British Association for Psychopharmacology. J Psychopharmacol 25, 997-1019.
35. Suribhatla S, DennisMS,Potter JF (2005)Astudy of statin use in the prevention of cognitive impairment of vascular origin in the UK. J Neurol Sci 229-230, 147-150.
36. Menezes AR, Lavie CJ, Milani RV, O'Keefe J (2012) The effects of statins on prevention of stroke and dementia: A review. J Cardiopulm Rehabil Prev 32, 240-249.
37. Baskys A, Cheng JX (2012) Pharmacological prevention and treatment of vascular dementia: Approaches and perspectives. Exp Gerontol 47, 887-891.
38. LevineDA, LangaKM(2011)Vascular cognitive impairment: Disease mechanisms and therapeutic implications. Neurotherapeutics 8, 361-373.
39. Jukema JW, Cannon CP, de Craen AJ, Westendorp RG, Trompet S (2012) The controversies of statin therapy:Weighing the evidence. J Am Coll Cardiol 60, 875-881.
40. Korczyn AD (2002) The complex nosological concept of vascular dementia. J Neurol Sci 203-204, 3-6.
41. Korczyn AD, Vakhapova V, Grinberg LT (2012) Vascular dementia. J Neurol Sci 322, 2-10.
42. Milionis HJ, Florentin M, Giannopoulos S (2008) Metabolic syndrome and Alzheimer's disease: A link to a vascular hypothesis? CNS Spectr 13, 606-613.
43. Birkenhager WH, Wang JG, Staessen JA (2001) Dementia and statins. Lancet 357, 880; 880-881.